The global IBD therapeutics market is estimated to grow significantly at a CAGR of around 5.0% during the forecast period. The rise in the number of IBD such as Crohn’s disease and ulcerative colitis is augmenting the growth of the global IBD therapeutics market. The increasing prevalence of IBD results in the need for research for the treatment of IBD and innovations in healthcare systems to manage this complex and costly disease. According to the CDC in the US, the incidence rate for Crohn’s disease was 3.1 to 14.6 cases per 100,000 people per year in 2015. The incidence rate of ulcerative colitis was 2.2 to 14.3 cases per 100,000 people per year in 2015. Moreover, the prevalence of IBD in Europe is increasing, according to the European Federation of Crohn's & Ulcerative Colitis Associations (EFCCA), there were 3.4 million cases of IBD in 2016. According to the WHO, the highest rates of IBD are found in, developed countries including the US and UK.
Request a free sample of our report on Global Inflammatory Bowel Disease (IBD) Therapeutics Market: https://www.omrglobal.com/request-sample/ibd-inflammatory-bowel-disease-therapeutics-market

The global IBD therapeutics market is segmented on the basis of disease type and treatment type. The disease type segment includes ulcerative colitis and Crohn’s disease. Crohn’s disease segment is estimated to dominate the market. The growth of the segment is attributed to the comparatively higher incidence of Crohn’s disease than ulcerative colitis. For Crohn’s and ulcerative colitis, the development of minimally invasive methods has been evolved with more caution as compared to other colorectal diseases. This is primarily due to disease-related characteristics that are concerned with IBD. The treatment type segment is further segmented into anti-inflammatory drugs and surgery. There is a range of anti-inflammatory drugs used for the treatment of IBD, such as immunosuppressants (methotrexate, ciclosporin, and azathioprine), steroids and biological drugs. These are usually the first step in the treatment of IBD.
A full report of Global Inflammatory Bowel Disease (IBD) Therapeutics Market Is available at https://www.omrglobal.com/industry-reports/ibd-inflammatory-bowel-disease-therapeutics-market

Global IBD Therapeutics Market Segmentation
By Disease Type
• Ulcerative Colitis
• Crohn’s Disease
By Treatment Type
• Surgery
• Anti- Inflammatory Drug Administration
o Steroids
o Immunosuppressant
o Biological Drugs
o Amino salicylates
o Others
Regional Analysis
• North America
o United States
o Canada
• Europe
o UK
o Germany
o France
o Italy
o Spain
o Rest of Europe
• Asia-Pacific
o China
o India
o Japan
o Rest of Asia-Pacific
• Rest of the World
Company Profiles
• Abbott Laboratories
• AbbVie Inc.
• Allergan, PLC
• Boehringer Ingelheim International GmbH
• Celgene Corp.
• Daiichi Sankyo Co. Ltd.
• Eli Lilly and Co.
• F. Hoffmann-La Roche AG
• GlaxoSmithKline PLC
• Johnson & Johnson Services Inc.
For more customized data, request for report customization @ https://www.omrglobal.com/report-customization/ibd-inflammatory-bowel-disease-therapeutics-market
About Us:

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting, and other research-based services.
For More Information, Visit https://www.omrglobal.com/
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +91 780-304-0404